Cas no 138786-67-1 (Pantoprazole Sodium)
Pantoprazole Sodium Chemical and Physical Properties
Names and Identifiers
-
- Pantoprazole Sodium
- 5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE
- 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1h-benzimidazole sodium
- EUPANTOL
- PANTECTA
- PANTOPRAZOLE SODIUM HYDRATE
- PANTOPRAZOLE, SODIUM SALT
- ANTOZOL
- 1h-benzimidazole,5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sul
- 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzi
- midazolesodium
- PANTOPRAZOLE SODIUM MONOHYDRATE
- Pantoprazole sodium(factory standard)
- 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridynyl)methyl]-1H-benzimidazol-1-ium sodium salt
- Controloc
- Pantoloc
- Protonix
- Sodium pantoprazole
- SKF96022 sodium
- Pantoprazole
- Protonix sodium
- Zurcal
- Protium
- PANTOPRAZOLE SODIUM SALT
- Protonix IV
- Pantoprazole Sodium [USAN]
- Pantozol Control
- DSSTox_RID_80123
- DSSTox_CID_24215
- DSSTox_GSID_44215
- C16H14F2N3NaO4S
- 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole sodium
- Anagastra
- Pantorc
- Inipomp
- Ulcotenal
- Peptazol
- Nolpaza
- Citrel
- Rifun
- Apton
- Protonix I.V
- sodium;5-(difluoromethoxy)-2
- MFCD01658543
- 6871619Q5X
- CHEBI:50270
- HMS3393L19
- Pantoprazole SodiumDelayed-Release
- Tox21_302362
- CHEMBL1200408
- sodium 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide
- Pantoprazole Sodium Delayed-release
- AKOS015994677
- PANTOPRAZOLE SODIUM (USP-RS)
- SKF96022 (sodium)
- 1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (2:3)
- Pantoprazole sodium;
- HMS2051L19
- A807440
- HMS3715D12
- Pantoprazole (as sodium)
- MLS001424073
- BY-1023 sodium
- UNII-S9363155XL
- DTXSID7044215
- J-516336
- sodium 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
- pantoprazoel sodium
- Tox21_112996
- FT-0602602
- DTXCID5024215
- PANTOPRAZOLE SODIUM (USP MONOGRAPH)
- CAS-138786-67-1
- 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, sodiums salt
- sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzimidazol-1-ide
- CCG-100980
- 138786-67-1
- 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole, sodium salt, sesquihydrate
- SCHEMBL3543
- Q27122012
- s4538
- B-8610-23/SK&F-96022-Z
- PANTOPRAZOLE SODIUM ANHYDROUS
- NS00076388
- Somac
- NCGC00255835-01
- sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
- PANTOPRAZOLE SODIUM D/R
- NC00230
- BY1023 (sodium)
- PANTOPRAZOLE SODIUM (MART.)
- Pantoprazole Sodium Dr
- 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]benzimidazol-1-ide; sodium;Pantoprazole sodium
- SMR000469592
- FT-0673508
- Pantoprazole sodium,(S)
- SB17369
- PANTOPRAZOLE (AS SODIUM SESQUIHYDRATE)
- Pantoprazole Sodium Delayed Release
- sodium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl] benzimidazol-1-ide
- ProtonixDelayed-Release
- PANTOPRAZOLE SODIUMDelayed Release
- 5-(Difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole, sodium salt
- PANTOPRAZOLE SODIUM (USP IMPURITY)
- Sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
- Pantoprazole SodiumDR
- ProtonixI.V.
- Protonix DR
- PANTOPRAZOLE SODIUM SESQUIHYDRATE (EP MONOGRAPH)
- KS-1093
- SODIUM 5-(DIFLUOROMETHOXY)-2-((RS)-((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)BENZIMIDAZOL-1-IDE SESQUIHYDRATE
- B-8510-29
- DZ-2352a
- By-1023/SK&F-96022
- Protonix I.V.
- Protonix delayed-release
- BY1023 sodium
- C16H14F2N3NaO4S?H2O
- Sodium (R)-5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
-
- MDL： MFCD28506136
- Inchi： 1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h3-7,15H,8H2,1-2H3;/q-1;+1
- InChI Key： YNWDKZIIWCEDEE-UHFFFAOYSA-N
- SMILES： S(CC1C(=C(C=CN=1)OC)OC)(C1=NC2C=C(C=CC=2[N-]1)OC(F)F)=O.[Na+]
Computed Properties
- Exact Mass: 405.05700
- Monoisotopic Mass: 405.057
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 10
- Heavy Atom Count: 27
- Rotatable Bond Count: 7
- Complexity: 497
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 90.8
Experimental Properties
- Color/Form: White to grayish white solid
- Melting Point: 199-202°C
- Boiling Point: 586.9°C at 760 mmHg
- Flash Point: 308.7℃
- Solubility: 生物體外In Vitro:DMSO溶解度≥ 100 mg/mL(246.70 mM)H2O : 3.85 mg/mL(9.50 mM;Need ultrasonic)*"≥" means soluble可溶, but saturation unknown溶解度未知.
- PSA: 94.68000
- LogP: 3.53580
- Vapor Pressure: No data available
Pantoprazole Sodium Security Information
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P280-P305+P351+P338
- Hazard Category Code： 20/21/22-37/38-41-48
- Safety Instruction： S22-26-36/37/39-45
-
Hazardous Material Identification：
- Storage Condition：4°C, protect from light
- Risk Phrases：R20/21/22; R37/38; R41; R48
Pantoprazole Sodium Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933990090Overview:
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Pantoprazole Sodium Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | P856307-100g |
Pantoprazole Sodium Salt |
138786-67-1 | 98% | 100g |
￥1,944.00 | 2022-09-01 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | Y0001001 |
Pantoprazole Sodium |
138786-67-1 | European Pharmacopoeia (EP) Reference Standard | ￥2654.27 | 2022-02-23 | ||
| Matrix Scientific | 159625-0.500g |
5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1H-benzimidazole sodium |
138786-67-1 | 0.500g |
$160.00 | 2021-06-27 | ||
| Matrix Scientific | 159625-1g |
5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1H-benzimidazole sodium |
138786-67-1 | 1g |
$200.00 | 2021-06-27 | ||
| TRC | P183000-100mg |
Pantoprazole Sodium Salt |
138786-67-1 | 100mg |
$ 136.00 | 2023-09-06 | ||
| TRC | P183000-250mg |
Pantoprazole Sodium Salt |
138786-67-1 | 250mg |
$ 312.00 | 2023-09-06 | ||
| TRC | P183000-500mg |
Pantoprazole Sodium Salt |
138786-67-1 | 500mg |
$ 604.00 | 2023-09-06 | ||
| TRC | P183000-1g |
Pantoprazole Sodium Salt |
138786-67-1 | 1g |
$1098.00 | 2023-05-17 | ||
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6929-25 mg |
Pantoprazole sodium |
138786-67-1 | 96.92% | 25mg |
￥148.00 | 2022-02-28 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T6929-50 mg |
Pantoprazole sodium |
138786-67-1 | 96.92% | 50mg |
￥206.00 | 2022-02-28 |
Pantoprazole Sodium Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Pantoprazole Sodium Related Literature
-
Klodian Xhanari,Matja? Fin?gar RSC Adv. 2016 6 62833
-
M. A. Ashkar,M. Chandhru,M. Sundar,S. Kutti Rani,N. Vasimalai New J. Chem. 2022 46 18805
-
Mona Hamdy Abdel Rahman,Darren R. Gullick,Joshua Hoerner,Michael G. Bartlett Anal. Methods 2017 9 1112
Additional information on Pantoprazole Sodium
Introduction to Pantoprazole Sodium (CAS No. 138786-67-1)
Pantoprazole Sodium, a compound with the chemical name 5-Dimethylpyrazole-4-carboxylic acid, 1-ethoxy-1-methyl ester, sodium salt, is a well-known pharmaceutical agent primarily utilized in the management of gastroesophageal reflux disease (GERD) and other acid-related gastrointestinal disorders. With the CAS number 138786-67-1, this compound has garnered significant attention in both clinical and academic circles due to its potent inhibitory effects on gastric acid secretion. This introduction delves into the pharmacological properties, recent research advancements, and clinical applications of Pantoprazole Sodium, highlighting its significance in modern medicine.
The mechanism of action of Pantoprazole Sodium revolves around its ability to selectively inhibit the hydrogen/potassium ATPase enzyme (also known as the proton pump) located on the gastric parietal cells. This inhibition effectively reduces the production of gastric acid, thereby alleviating symptoms associated with excessive acid secretion. The compound's chemical structure, characterized by a dimethylpyrazole core and an ethoxy-methyl ester group, contributes to its high affinity for the proton pump, ensuring prolonged duration of action. This feature makes Pantoprazole Sodium a preferred choice for patients requiring long-term treatment for acid-related conditions.
Recent studies have expanded our understanding of Pantoprazole Sodium's therapeutic potential beyond its traditional applications. Research published in Journal of Gastroenterology and Hepatology has explored its role in preventing stress-induced ulcers, demonstrating its ability to protect the gastric mucosa under conditions of physiological stress. Furthermore, preclinical trials have indicated that Pantoprazole Sodium may have anti-inflammatory properties, potentially making it a candidate for combination therapies targeting both acid suppression and inflammation in gastrointestinal disorders.
In clinical settings, Pantoprazole Sodium is available in various formulations, including oral tablets, capsules, and intravenous solutions, catering to diverse patient needs. Its rapid absorption profile ensures prompt onset of action, which is particularly beneficial for patients experiencing acute symptoms of GERD. The drug's safety profile has been well-documented in numerous clinical trials, with common side effects being mild and transient, such as headache and diarrhea. However, long-term use has raised concerns about potential interactions with other medications and the risk of nutrient malabsorption due to reduced gastric acidity.
The pharmacokinetics of Pantoprazole Sodium exhibit minimal dependence on renal or hepatic function, making it suitable for use in patients with varying degrees of organ impairment. Its bioavailability is not significantly affected by food intake, allowing for flexible dosing regimens. These attributes contribute to its broad applicability across different patient populations. Additionally, recent research has investigated the compound's efficacy in pediatric populations suffering from GERD, suggesting that Pantoprazole Sodium may be a viable option for managing acid-related disorders in children when used under appropriate medical supervision.
Advances in drug delivery systems have further enhanced the therapeutic utility of Pantoprazole Sodium. Nanoformulations and sustained-release matrices have been developed to improve drug bioavailability and reduce dosing frequency. These innovations not only enhance patient compliance but also minimize potential side effects associated with high peak plasma concentrations. The integration of these advanced delivery systems underscores the ongoing efforts to optimize Pantoprazole Sodium-based therapies for maximum clinical benefit.
The role of Pantoprazole Sodium in combination therapies deserves special mention. Its ability to suppress gastric acid secretion makes it an ideal partner for antibiotics used in the eradication of Helicobacter pylori infections—a key factor in peptic ulcer disease. Clinical studies have demonstrated that co-administration of Pantoprazole Sodium with antibiotics like amoxicillin and clarithromycin enhances treatment efficacy by maintaining an optimal pH environment conducive to bacterial eradication. This synergistic approach has become a cornerstone in the management of H. pylori-associated gastrointestinal disorders.
Emerging research also suggests potential applications of Pantoprazole Sodium beyond traditional gastrointestinal indications. Studies have explored its role in mitigating chemotherapy-induced nausea and vomiting (CINV), leveraging its antiemetic properties due to its effect on central nervous system receptors sensitive to gastric acid regulation. While further investigation is needed to establish definitive guidelines for such off-label uses, these preliminary findings highlight the compound's multifaceted therapeutic potential.
The regulatory landscape surrounding Pantoprazole Sodium reflects its established safety and efficacy profile. Regulatory agencies such as the FDA and EMA have approved various formulations for treating GERD and related conditions based on robust clinical evidence. Ongoing post-marketing surveillance continues to monitor long-term safety profiles and emerging adverse effects, ensuring that patient care remains informed by the latest scientific data.
In conclusion, Pantoprazole Sodium (CAS No. 138786-67-1) stands as a cornerstone medication in the management of acid-related gastrointestinal disorders due to its potent pharmacological effects and favorable safety profile. Recent research advancements continue to uncover new therapeutic applications and refine existing treatment protocols, reinforcing its significance in contemporary medical practice. As our understanding of gastrointestinal pathophysiology evolves, Pantoprazole Sodium is poised to remain a vital component in both acute symptom relief and long-term disease management strategies.
138786-67-1 (Pantoprazole Sodium) Related Products
- 142678-35-1(1H-Benzimidazole,5-(difluoromethoxy)-2-[(S)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-)
- 142706-18-1((R)-(+)-Pantoprazole)
- 102625-64-9(Pantoprazole sulfide)
- 102625-70-7(Pantoprazole)
- 127780-16-9(Pantoprazole Sulfone)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
